Page 1 of 129
NSG 552 PSYCHOPHARMACOLOGY EXAM COMPREHENSIVE QUESTIONS
AND CORRECT ANSWERS LATEST EDITION 2026
NSG 552 PSYCHOPHARMACOLOGY: QUESTIONS WITH RATIONALES
SUMMARIZED 10-POINT EXAM COVERAGE
1. Neurobiology & Neurotransmission: Synaptic transmission, receptor pharmacology,
neurotransmitter systems, and signal transduction.
2. Pharmacokinetics & Pharmacodynamics: Absorption, distribution, metabolism
(CYP450), excretion, half-life, and therapeutic index.
3. Depressive & Anxiety Disorders: Antidepressants (SSRIs, SNRIs, TCAs, MAOIs),
anxiolytics, and mood stabilizers.
4. Psychotic Disorders: First- and second-generation antipsychotics, adverse effects, and
metabolic monitoring.
5. Bipolar & Mood Disorders: Lithium, anticonvulsants, and treatment of acute mania and
maintenance.
6. Substance Use Disorders: Alcohol, opioid, and stimulant pharmacotherapy, withdrawal
management, and harm reduction.
7. ADHD & Neurodevelopmental Disorders: Stimulant and non-stimulant medications,
dosing, and adverse effects.
8. Neurocognitive & Geriatric Psychopharmacology: Dementia, Alzheimer's, and age-
related pharmacokinetic changes.
1|Page
,Page 2 of 129
9. Special Populations & Lifespan Considerations: Pregnancy, lactation, pediatrics, and
cultural considerations.
10. Ethical, Legal & Prescribing Considerations: Informed consent, off-label use, DEA
regulations, and collaborative practice.
EXAM 1: FOUNDATIONS & NEUROBIOLOGY
Questions 1–100
Section 1: Neurobiology & Neurotransmission (Q1–Q35)
Question 1
During synaptic transmission, which of the following sequences correctly describes the
process at a chemical synapse?
A. Action potential → neurotransmitter release → receptor binding → postsynaptic potential
B. Neurotransmitter release → action potential → receptor binding → reuptake
C. Receptor binding → action potential → neurotransmitter release → degradation
D. Action potential → receptor binding → neurotransmitter release → reuptake
Answer: A
Rationale: The correct sequence is: an action potential arrives at the presynaptic terminal →
neurotransmitters are released into the synaptic cleft → they bind to receptors on the
postsynaptic membrane → this generates a postsynaptic potential (excitatory or inhibitory).
Reuptake and degradation are termination mechanisms that follow.
Question 2
Which neurotransmitter is the primary excitatory neurotransmitter in the central nervous
system?
A. GABA
B. Glutamate
2|Page
,Page 3 of 129
C. Dopamine
D. Serotonin
Answer: B
Rationale: Glutamate is the primary excitatory neurotransmitter in the CNS, responsible for
most excitatory synaptic transmission. GABA is the primary inhibitory neurotransmitter.
Dopamine and serotonin are modulatory neurotransmitters.
Question 3
A PMHNP is explaining the mechanism of action of benzodiazepines to a patient. Which
GABA-A receptor subunit composition is the primary target of benzodiazepines?
A. α1, β2, γ2
B. α4, β1, γ1
C. α5, β3, δ
D. α6, β2, γ3
Answer: A
Rationale: Benzodiazepines bind to the interface between the α and γ subunits of the GABA-A
receptor. The most common composition is α1, β2, and γ2 subunits. This binding enhances the
inhibitory effect of GABA, leading to sedation, anxiolysis, and muscle relaxation.
Question 4
Which enzyme is the rate-limiting step in the synthesis of catecholamines (dopamine,
norepinephrine, epinephrine)?
A. Dopamine beta-hydroxylase
B. Tyrosine hydroxylase
C. Aromatic L-amino acid decarboxylase
D. Phenylethanolamine N-methyltransferase
3|Page
, Page 4 of 129
Answer: B
Rationale: Tyrosine hydroxylase converts tyrosine to L-DOPA, which is the rate-limiting step in
catecholamine synthesis. This enzyme is regulated by feedback inhibition from downstream
products.
Question 5
Norepinephrine is synthesized from dopamine through the action of which enzyme?
A. Tyrosine hydroxylase
B. Dopamine beta-hydroxylase
C. Aromatic L-amino acid decarboxylase
D. Monoamine oxidase
Answer: B
Rationale: Dopamine beta-hydroxylase (DBH) converts dopamine to norepinephrine inside
synaptic vesicles. This enzyme is a marker for noradrenergic neurons.
Question 6
A PMHNP is teaching a student about the mesolimbic pathway. Which of the following
functions is primarily associated with this pathway?
A. Motor control
B. Reward and motivation
C. Executive function
D. Hormone regulation
Answer: B
Rationale: The mesolimbic dopamine pathway projects from the ventral tegmental area (VTA)
to the nucleus accumbens and is central to reward, motivation, and reinforcement. It is heavily
implicated in substance use disorders and the positive symptoms of schizophrenia.
4|Page
NSG 552 PSYCHOPHARMACOLOGY EXAM COMPREHENSIVE QUESTIONS
AND CORRECT ANSWERS LATEST EDITION 2026
NSG 552 PSYCHOPHARMACOLOGY: QUESTIONS WITH RATIONALES
SUMMARIZED 10-POINT EXAM COVERAGE
1. Neurobiology & Neurotransmission: Synaptic transmission, receptor pharmacology,
neurotransmitter systems, and signal transduction.
2. Pharmacokinetics & Pharmacodynamics: Absorption, distribution, metabolism
(CYP450), excretion, half-life, and therapeutic index.
3. Depressive & Anxiety Disorders: Antidepressants (SSRIs, SNRIs, TCAs, MAOIs),
anxiolytics, and mood stabilizers.
4. Psychotic Disorders: First- and second-generation antipsychotics, adverse effects, and
metabolic monitoring.
5. Bipolar & Mood Disorders: Lithium, anticonvulsants, and treatment of acute mania and
maintenance.
6. Substance Use Disorders: Alcohol, opioid, and stimulant pharmacotherapy, withdrawal
management, and harm reduction.
7. ADHD & Neurodevelopmental Disorders: Stimulant and non-stimulant medications,
dosing, and adverse effects.
8. Neurocognitive & Geriatric Psychopharmacology: Dementia, Alzheimer's, and age-
related pharmacokinetic changes.
1|Page
,Page 2 of 129
9. Special Populations & Lifespan Considerations: Pregnancy, lactation, pediatrics, and
cultural considerations.
10. Ethical, Legal & Prescribing Considerations: Informed consent, off-label use, DEA
regulations, and collaborative practice.
EXAM 1: FOUNDATIONS & NEUROBIOLOGY
Questions 1–100
Section 1: Neurobiology & Neurotransmission (Q1–Q35)
Question 1
During synaptic transmission, which of the following sequences correctly describes the
process at a chemical synapse?
A. Action potential → neurotransmitter release → receptor binding → postsynaptic potential
B. Neurotransmitter release → action potential → receptor binding → reuptake
C. Receptor binding → action potential → neurotransmitter release → degradation
D. Action potential → receptor binding → neurotransmitter release → reuptake
Answer: A
Rationale: The correct sequence is: an action potential arrives at the presynaptic terminal →
neurotransmitters are released into the synaptic cleft → they bind to receptors on the
postsynaptic membrane → this generates a postsynaptic potential (excitatory or inhibitory).
Reuptake and degradation are termination mechanisms that follow.
Question 2
Which neurotransmitter is the primary excitatory neurotransmitter in the central nervous
system?
A. GABA
B. Glutamate
2|Page
,Page 3 of 129
C. Dopamine
D. Serotonin
Answer: B
Rationale: Glutamate is the primary excitatory neurotransmitter in the CNS, responsible for
most excitatory synaptic transmission. GABA is the primary inhibitory neurotransmitter.
Dopamine and serotonin are modulatory neurotransmitters.
Question 3
A PMHNP is explaining the mechanism of action of benzodiazepines to a patient. Which
GABA-A receptor subunit composition is the primary target of benzodiazepines?
A. α1, β2, γ2
B. α4, β1, γ1
C. α5, β3, δ
D. α6, β2, γ3
Answer: A
Rationale: Benzodiazepines bind to the interface between the α and γ subunits of the GABA-A
receptor. The most common composition is α1, β2, and γ2 subunits. This binding enhances the
inhibitory effect of GABA, leading to sedation, anxiolysis, and muscle relaxation.
Question 4
Which enzyme is the rate-limiting step in the synthesis of catecholamines (dopamine,
norepinephrine, epinephrine)?
A. Dopamine beta-hydroxylase
B. Tyrosine hydroxylase
C. Aromatic L-amino acid decarboxylase
D. Phenylethanolamine N-methyltransferase
3|Page
, Page 4 of 129
Answer: B
Rationale: Tyrosine hydroxylase converts tyrosine to L-DOPA, which is the rate-limiting step in
catecholamine synthesis. This enzyme is regulated by feedback inhibition from downstream
products.
Question 5
Norepinephrine is synthesized from dopamine through the action of which enzyme?
A. Tyrosine hydroxylase
B. Dopamine beta-hydroxylase
C. Aromatic L-amino acid decarboxylase
D. Monoamine oxidase
Answer: B
Rationale: Dopamine beta-hydroxylase (DBH) converts dopamine to norepinephrine inside
synaptic vesicles. This enzyme is a marker for noradrenergic neurons.
Question 6
A PMHNP is teaching a student about the mesolimbic pathway. Which of the following
functions is primarily associated with this pathway?
A. Motor control
B. Reward and motivation
C. Executive function
D. Hormone regulation
Answer: B
Rationale: The mesolimbic dopamine pathway projects from the ventral tegmental area (VTA)
to the nucleus accumbens and is central to reward, motivation, and reinforcement. It is heavily
implicated in substance use disorders and the positive symptoms of schizophrenia.
4|Page
